5-t-butyl-1,3-dioxolene-2-one-4-carboxylic acid | 188525-92-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: 5-t-butyl-1,3-dioxolene-2-one-4-carboxylic acid
• 英文别名: 5-tert-butyl-2-oxo-1,3-dioxol-4-carboxylic acid；5-(Tert-butyl)-2-oxo-1,3-dioxole-4-carboxylic acid；5-tert-butyl-2-oxo-1,3-dioxole-4-carboxylic acid
• CAS: 188525-92-0
• 化学式: C₈H₁₀O₅
• 分子量: 186.164
• InChiKey: WBWRQRLPQKEWEG-UHFFFAOYSA-N

物化性质

• 沸点：
  248.3±50.0 °C(Predicted)
• 密度：
  1.378±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-t-butyl-1,3-dioxolene-2-one-4-carboxylic acid 在 ice 、 氯仿 、 四丁基硼氢化铵 、 盐酸 、 Brine 、 magnesium sulfate 、 silica gel 、 ethyl acetate n-hexane 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 、 草酰氯 为溶剂， 反应 2.0h， 以to give the titled compound (854 mg) as a colorless oil的产率得到4-t-butyl-5-hydroxymethyl-1,3-dioxol-2-one
  参考文献：
  名称：

  COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY

  摘要：

  本发明提供了具有优越的TAFIa抑制活性的化合物。它们是由以下化学式(I)表示的二氢咪唑喹啉化合物或其药学上可接受的盐：其中R是氢原子或C1-10烷基；R1是氢原子、C1-10烷基、C3-8环烷基或具有以下化学式Ia或Ib表示的取代基：其中R3是C1-6烷基；R4是C1-6烷基、C3-8环烷基或苄基；R2是氢原子或具有以下化学式Ic或Id表示的取代基：

  公开号：

  US20120172598A1
• 作为产物：
  描述：

  特戊酰基乙酸乙酯 在 dirhodium tetraacetate 、 palladium hydroxide - carbon 4-二甲氨基吡啶 、 对甲苯磺酰叠氮 、 氢气 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醇 、 水 、 甲苯 、 乙腈 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 生成 5-t-butyl-1,3-dioxolene-2-one-4-carboxylic acid
  参考文献：
  名称：

  A general synthesis of dioxolenone prodrug moieties

  摘要：

  A general method for the synthesis of dioxolenone prodrug moieties from appropriately substituted beta-ketoesters is described. This novel and versatile sequence allows for the synthesis of alkyl- or aryl-substituted dioxolenone alcohols 8 or bromides 9. Coupling of the bromides 9 to prepare bis-dioxolenone phosphonate prodrug esters is also presented. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)02386-3

文献信息

• [EN] HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES<br/>[FR] COMPOSES ANTIVIRAUX HETEROCYCLIQUES COMPORTANT DES GROUPES FONCTIONNELS METABOLISABLES ET LEURS UTILISATIONS
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2005097760A1

  公开（公告）日：2005-10-20

  The present invention relates to substituted prodrug and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.

  本发明涉及替代前药及其组合物，用于治疗或预防丙型肝炎病毒（HCV）感染。具体而言，本发明涉及替代二苯基、二杂环芳基和混合苯基杂环芳基替代的五元杂环化合物的前药，包含这些化合物的组合物以及利用这些化合物和组合物来抑制HCV复制和/或增殖作为治疗方法，以治疗和/或预防人类和动物中的HCV感染。
• [EN] COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY<br/>[FR] COMPOSES AYANT UNE ACTIVITE INHIBITRICE DU TAFIA
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2011034215A1

  公开（公告）日：2011-03-24

  The present invention provides compounds having superior TAFIa inhibitory activity. They are dihydroimidazoquinoline compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof: (I) wherein R is a hydrogen atom or a C1-10 alkyl group; R1 is a hydrogen atom, a C1-10 alkyl group, a C3-8 cycloalkyl group or a substituent having the structure represented by the following formula Ia or Ib: (Ia) (Ib) where R3 is a C1-6 alkyl group; R4 is a C1-6 alkyl group, a C3-8 cycloalkyl group, or a benzyl group; and R2 is a hydrogen atom or a substituent having the structure represented by the following formula Ic or Id:(Ic) (Id)

  本发明提供了具有优越的TAFIa抑制活性的化合物。它们是由以下式(I)表示的二氢咪唑喹啉化合物或其药学上可接受的盐：(I)其中R是氢原子或C1-10烷基基团；R1是氢原子、C1-10烷基基团、C3-8环烷基基团或具有以下式Ia或Ib所代表的结构的取代基：(Ia) (Ib)其中R3是C1-6烷基基团；R4是C1-6烷基基团、C3-8环烷基基团或苄基；R2是氢原子或具有以下式Ic或Id所代表的结构的取代基：(Ic) (Id)
• Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
  申请人：Singh Rajinder

  公开号：US20050239751A1

  公开（公告）日：2005-10-27

  The present invention relates to substituted prodrug and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.

  本发明涉及代替前药及其组合物，用于治疗或预防丙型肝炎病毒（HCV）感染。具体而言，本发明涉及取代二苯基、双杂环芳基和混合苯基杂芳基取代的五元杂环化合物的前药，包括该化合物的组合物，以及使用这些化合物和组合物来抑制HCV复制和/或增殖，作为治疗和/或预防人类和动物HCV感染的治疗方法。
• A general synthesis of dioxolenone prodrug moieties
  作者：Chong-Qing Sun、Peter T.W. Cheng、Jay Stevenson、Tamara Dejneka、Baerbel Brown、Tammy C. Wang、Jeffrey A. Robl、Michael A. Poss

  DOI：10.1016/s0040-4039(01)02386-3

  日期：2002.2

  A general method for the synthesis of dioxolenone prodrug moieties from appropriately substituted beta-ketoesters is described. This novel and versatile sequence allows for the synthesis of alkyl- or aryl-substituted dioxolenone alcohols 8 or bromides 9. Coupling of the bromides 9 to prepare bis-dioxolenone phosphonate prodrug esters is also presented. (C) 2002 Elsevier Science Ltd. All rights reserved.
• COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY
  申请人：Amada Hideaki

  公开号：US20120172598A1

  公开（公告）日：2012-07-05

  The present invention provides compounds having superior TAFIa inhibitory activity. They are dihydroimidazoquinoline compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof: wherein R is a hydrogen atom or a C 1-10 alkyl group; R 1 is a hydrogen atom, a C 1-10 alkyl group, a C 3-8 cycloalkyl group or a substituent having the structure represented by the following formula Ia or Ib: where R 3 is a C 1-6 alkyl group; R 4 is a C 1-6 alkyl group, a C 3-8 cycloalkyl group, or a benzyl group; and R 2 is a hydrogen atom or a substituent having the structure represented by the following formula Ic or Id:

  本发明提供了具有优越的TAFIa抑制活性的化合物。它们是由以下化学式(I)表示的二氢咪唑喹啉化合物或其药学上可接受的盐：其中R是氢原子或C1-10烷基；R1是氢原子、C1-10烷基、C3-8环烷基或具有以下化学式Ia或Ib表示的取代基：其中R3是C1-6烷基；R4是C1-6烷基、C3-8环烷基或苄基；R2是氢原子或具有以下化学式Ic或Id表示的取代基：